Immunology Faculty Member - Stuart Schreiber, PhD

Stuart Schreiber, PhD

Broad Institute of MIT and Harvard
7 Cambridge Center
Room 3013
Cambridge, MA 02142
Tel: 617-714-7080
Fax: 617-714-8969
Email: stuart_schreiber@harvard.edu
Visit my lab page here.



Stuart Schreiber's lab has reported on a number of small-molecule-based advances, including:

- co-discovering (also: Sol Snyder and David Sabatini) the protein kinase mTOR and illuminating intracellular signaling by mTOR and the protein phosphatase calcineurin (demonstrating for the first time that drugs can result from targeting protein kinases and phosphatases and intracellular signal transduction in general, each perceived as extremely challenging (‘undruggable’) in the 1980s and now a routine and central element of drug discovery);

- conceiving and developing, with Gerald Crabtree, small-molecule dimerizers that activate cellular processes by enforced proximity (widely used in research and now being tested in human clinical trials for treatment of prostate cancer);

- discovering the histone deacetylase-1 (HDAC1) and class II HDACs and illuminating their role in gene regulation (demonstrating for the first time that drugs can result from targeting chromatin-modifying enzymes);

- illuminating the relationship of small-molecule sensitivity to the features of cells and using these relationships to explore cell states – including a myofibroblastic-like cell state associated with the resistance of cancers to therapeutic agents;

- developing diversity-oriented synthesis, building on generations of work in synthetic methodology and target-oriented synthesis to create screening candidates whose stereochemical and skeletal structural diversity enabled the discovery of small-molecule probes targeting otherwise challenging targets such as transcription factors, oncogenes, protein/protein and protein/DNA interactions, and chromatin, and processes such as transdifferentiation;

- illuminating the basis role of apolipoprotein E in brain injury and degeneration and developing apoE-based therapeutics;

The primary focus of his group over the next several years will be on: 1) exploring the role of a myofibroblastic cell state in human pathology; 2) understanding the role of the clearance of molecular and cellular debris in brain health; and 3) developing a binding-based approach to drug discovery.



Last Update: 6/18/2018



Publications

"Signaling network model of chromatin”, S L Schreiber and B E Bernstein, Cell, 2002, 111, 771-778.

“Integration Growth Factor and nutrient signaling: Implications for cancer biology” Alykhan F. Shamji, Paul Nghiem, Stuart L. Schreiber, Molecular Cell, 2003, 12, 271-280.

“Small Molecules: The missing link in the central dogma” S. L. Schreiber, Nat. Chem. Biol., 2005, 1, 64-66.



© 2016 President and Fellows
of Harvard College